Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

ANI Pharmaceuticals has disclosed the outcomes of its NEW DAY trial, assessing Iluvien 0.19mg, in people with diabetic macular oedema.

Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the ...

ANI Pharmaceuticals (ANIP) stock drops as its Iluvien implant fails in a clinical trial versus Eylea marketed by Regeneron ...

Aldershot, UK, September 2020 – The Scottish Medicines Consortium (SMC) has accepted ILUVIEN ® (190µg fluocinolone acetonide (FAc) intravitreal implant in applicator) for use within NHS Scotland for ...

In ANI's New Day trial, patients were randomized to an induction phase to receive either a single Iluvien injection or a series of five monthly injections of aflibercept, followed by supplemental ...

ANI Pharmaceuticals (ANIP) announced results from the NEW DAY clinical trial of ILUVIEN, or fluocinolone acetonide intravitreal implant, 0.19 mg ...

Iluvien was approved by the Food and Drug Administration back in 2014 for the treatment of DME in patients who were previously treated with corticosteroids without a clinically significant rise in ...

The National Institute for Health and Care Excellence has issued final guidance recommending Alimera Science's Iluvien (fluocinolone acetonide intravitreal implant) as an option for patients with ...

pSivida Corp. Announces New ILUVIEN® PDUFA Date of October 17, 2013 WATERTOWN, Mass.--(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV - News), a leader in developing sustained release, drug delivery ...

pSivida (PSDV) has a very important binary event upcoming on October 17, 2013; this is the PDUFA date for Iluvien, an ocular implant for diabetic macular edema that was licensed to Alimera (ALIM ...

Scottish cost regulators have rejected National Health Service funding for Alimera Science's eye implant Iluvien in patients with diabetic macular oedema, on grounds that it is too expensive. Scottish ...